Structure Therapeutics reported positive Phase II data for its oral GLP-1 receptor agonist aleniglipron , demonstrating dose-dependent weight loss of up to ~16% with no clear plateau and a tolerable safety profile
It implies controlled studies in human beings, with defined endpoints, that tell us whether a compound does what it is claimed to do
The highest dose helped patients lose 28.3 percent of their weight, or 70.3 pounds, on average over 80 weeks, against 2.2 percent for placebo, among those who stayed on the drug, and that about 45 percent of the 2,500 trial patients achieved 30 percent or more weight loss
Totally recommend
How semaglutide and tirzepatide work Both semaglutide and tirzepatide are prescription medications that mimic a hormone called glucagon-like peptide-1 (GLP-1)
In this post, well break down exactly what GLP-1 does, how food can help support it naturally, and what to know if youre thinking about taking a GLP-1 medication